
Sensei Biotherapeutics Investor Relations Material
Latest events

Study Update
Sensei Biotherapeutics
Access the full event backlog
Slides, Transcripts, and Reports from 12,000+ public companies
Latest reports from Sensei Biotherapeutics Inc
Access all reports
Sensei Biotherapeutics, Inc. is an immuno-oncology company dedicated to the discovery and development of next-generation therapeutics aimed at treating cancer patients. The company's innovative approach is centered on its TMAb™ (Tumor Microenvironment Activated biologics) platform, which develops conditionally active therapeutics. These therapeutics are designed to selectively disable checkpoints and other immunosuppressive signals in the tumor microenvironment, thereby unleashing T cells against tumors. Among its pipeline, the lead investigational candidate is SNS-101, a conditionally active antibody tailored to block the V-domain Ig suppressor of T cell activation (VISTA) checkpoint within the tumor's low pH environment, where VISTA suppresses T cell activity by binding the PSGL-1 receptor. The company is headquartered in Rockville, Maryland, with an additional office in Boston, Massachusetts, and its shares are listed on the Nasdaq.
Latest articles
)
Robert G. Hagstrom: Darwinian Investing and Multidisciplinary Wisdom
Robert G. Hagstrom, author of The Warren Buffett Way, explores how interdisciplinary thinking shapes his investing, from Adler's reading to Darwinian markets.
7 Feb 2025
)
Quartr Brings Stories Behind the Numbers to Light
Quartr simplifies access to IR material and puts qualitative insights and company narratives front and center.
3 Feb 2025
)
The Evolution of the IRO Role: Staying Informed and Strategic With Quartr Pro
Staying informed is critical for IROs. Quartr Pro simplifies gathering market insights and narrative positioning with unprecedented speed and precision.
3 Feb 2025
Ticker symbol
SNSE
Country
🇺🇸 United States